KR20120110000A - 2-카르복스아미드-7-피페라지닐-벤조푸란 유도체 774 - Google Patents
2-카르복스아미드-7-피페라지닐-벤조푸란 유도체 774 Download PDFInfo
- Publication number
- KR20120110000A KR20120110000A KR1020117031427A KR20117031427A KR20120110000A KR 20120110000 A KR20120110000 A KR 20120110000A KR 1020117031427 A KR1020117031427 A KR 1020117031427A KR 20117031427 A KR20117031427 A KR 20117031427A KR 20120110000 A KR20120110000 A KR 20120110000A
- Authority
- KR
- South Korea
- Prior art keywords
- ethyl
- alkyl
- piperazin
- pyridin
- benzofuran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- SXDJJQWHXHEGKG-UHFFFAOYSA-N CC(N(CCc1c2)c1ccc2C(CBr)=O)=O Chemical compound CC(N(CCc1c2)c1ccc2C(CBr)=O)=O SXDJJQWHXHEGKG-UHFFFAOYSA-N 0.000 description 1
- JSIPHSYCUYMXOI-UHFFFAOYSA-N CN(C)C(C1=CC2=CCCC(N3CCN(CCc(cc4)ncc4F)CC3)=C2O1)=O Chemical compound CN(C)C(C1=CC2=CCCC(N3CCN(CCc(cc4)ncc4F)CC3)=C2O1)=O JSIPHSYCUYMXOI-UHFFFAOYSA-N 0.000 description 1
- RDVVICBMWMYFDS-UHFFFAOYSA-N CN(C)C(c1cc2cc(F)cc(N3CCN(Cc4ccccc4)CC3)c2[o]1)=O Chemical compound CN(C)C(c1cc2cc(F)cc(N3CCN(Cc4ccccc4)CC3)c2[o]1)=O RDVVICBMWMYFDS-UHFFFAOYSA-N 0.000 description 1
- ICBLNAUTYHYELQ-UHFFFAOYSA-N CN(Cc1cccnc1)C(c1cc2cccc(N3CCN(CCc4ccccn4)CC3)c2[o]1)=O Chemical compound CN(Cc1cccnc1)C(c1cc2cccc(N3CCN(CCc4ccccn4)CC3)c2[o]1)=O ICBLNAUTYHYELQ-UHFFFAOYSA-N 0.000 description 1
- BKNCIECSNAJDAG-UHFFFAOYSA-N Cc(cc1)ccc1S(OCCc(nccc1)c1OC)(=O)=O Chemical compound Cc(cc1)ccc1S(OCCc(nccc1)c1OC)(=O)=O BKNCIECSNAJDAG-UHFFFAOYSA-N 0.000 description 1
- XIKBBDZPWPLOFN-UHFFFAOYSA-N O=C(c1cc(cccc2N3CCN(CCc4ccccn4)CC3)c2[o]1)NCc1ncccc1 Chemical compound O=C(c1cc(cccc2N3CCN(CCc4ccccn4)CC3)c2[o]1)NCc1ncccc1 XIKBBDZPWPLOFN-UHFFFAOYSA-N 0.000 description 1
- ASTHUBITKLQRCZ-UHFFFAOYSA-N O=C(c1cc2cccc(N3CCNCC3)c2[o]1)N1CCC1 Chemical compound O=C(c1cc2cccc(N3CCNCC3)c2[o]1)N1CCC1 ASTHUBITKLQRCZ-UHFFFAOYSA-N 0.000 description 1
- PAQCZDXYXLCTFI-UHFFFAOYSA-N Oc1cccc(CNC(c2cc(cccc3N4CCN(CCc5ccccn5)CC4)c3[o]2)=O)c1 Chemical compound Oc1cccc(CNC(c2cc(cccc3N4CCN(CCc5ccccn5)CC4)c3[o]2)=O)c1 PAQCZDXYXLCTFI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22165709P | 2009-06-30 | 2009-06-30 | |
| US61/221,657 | 2009-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20120110000A true KR20120110000A (ko) | 2012-10-09 |
Family
ID=43381415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020117031427A Withdrawn KR20120110000A (ko) | 2009-06-30 | 2010-06-29 | 2-카르복스아미드-7-피페라지닐-벤조푸란 유도체 774 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8367676B2 (enExample) |
| EP (1) | EP2448934B1 (enExample) |
| JP (1) | JP5767211B2 (enExample) |
| KR (1) | KR20120110000A (enExample) |
| CN (1) | CN102482264B (enExample) |
| AR (1) | AR077301A1 (enExample) |
| AU (1) | AU2010266753B2 (enExample) |
| BR (1) | BRPI1014222A2 (enExample) |
| CA (1) | CA2765475A1 (enExample) |
| MX (1) | MX2011013449A (enExample) |
| RU (1) | RU2011152516A (enExample) |
| TW (1) | TW201103922A (enExample) |
| UY (1) | UY32744A (enExample) |
| WO (1) | WO2011002405A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367676B2 (en) | 2009-06-30 | 2013-02-05 | Astrazeneca Ab | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
| CA2821480A1 (en) | 2010-12-20 | 2012-06-28 | Astrazeneca Ab | 2-carboxamide-4-piperazinyl-benzofuran derivative |
| CN102993186B (zh) * | 2012-12-20 | 2015-11-18 | 北京海步国际医药科技发展有限公司 | 一种新型的哌嗪衍生物 |
| US20160002273A1 (en) * | 2013-03-07 | 2016-01-07 | Glaxosmithkline Llc | Thieno[3,2-d]pyrimidine-6-carboxamides and analogues as sirtuin modulators |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| JP7532385B2 (ja) * | 2019-01-31 | 2024-08-13 | 杏林製薬株式会社 | １５－ｐｇｄｈ阻害薬 |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| WO2021243421A1 (en) * | 2020-06-05 | 2021-12-09 | Monash University | Dual kinase-bromodomain inhibitors |
| WO2022060764A1 (en) * | 2020-09-18 | 2022-03-24 | Merck Sharp & Dohme Corp. | Modified benzofuran-carboxamides as glucosylceramide synthase inhibitors |
| CN117430574B (zh) * | 2023-12-20 | 2024-03-22 | 潍坊医学院 | 一种苯并呋喃衍生物及其制备方法、用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9125900D0 (en) * | 1991-12-05 | 1992-02-05 | Wyeth John & Brother Ltd | Piperazine derivatives |
| DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| CA2297825C (en) * | 1997-07-25 | 2006-03-14 | H. Lundbeck A/S | Indole and 2,3-dihydroindole derivatives, their preparation and use |
| AR022303A1 (es) | 1999-01-22 | 2002-09-04 | Lundbeck & Co As H | Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion |
| JP2005501019A (ja) | 2001-06-15 | 2005-01-13 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ６レセプター親和性を有する４−ピペラジニルインドール誘導体 |
| CA2488761C (en) * | 2002-06-10 | 2011-05-31 | Bayer Healthcare Ag | 2-benzofuryl or benzothiophenyl-quinuclidinyl amides as nicotinic acetylcholine receptor inhibitors |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| DE10259244A1 (de) * | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | N-(Indolethyl-)cycloamin-Verbindungen |
| DE10326940A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| DE10326939A1 (de) * | 2003-06-16 | 2005-01-05 | Merck Patent Gmbh | Indol-Derivate |
| WO2005077885A1 (en) | 2004-02-06 | 2005-08-25 | Yale University | Ruthenium-catalyzed hydroamination of olefins |
| WO2006062481A1 (en) | 2004-12-09 | 2006-06-15 | Biovitrum Ab | New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders . |
| WO2007053093A1 (en) | 2005-11-04 | 2007-05-10 | Astrazeneca Ab | Chroman compounds as 5 ht1b antagonists |
| AR059356A1 (es) | 2006-02-14 | 2008-03-26 | Astrazeneca Ab | Nuevos radioligandos |
| WO2008037681A1 (en) | 2006-09-26 | 2008-04-03 | Glaxo Group Limited | 5-{2-[4-(2-methyl-5-quinolinyl)-l-piperidinyl] ethyl} quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairement, psychotic disorders, anxiety, depression, etc. |
| KR20090076962A (ko) | 2006-11-09 | 2009-07-13 | 에프. 호프만-라 로슈 아게 | 인돌 및 벤조퓨란 2-카복스아마이드 유도체 |
| US8367676B2 (en) | 2009-06-30 | 2013-02-05 | Astrazeneca Ab | 2-carboxamide-7-piperazinyl-benzofuran derivatives 774 |
-
2010
- 2010-06-28 US US12/824,567 patent/US8367676B2/en not_active Expired - Fee Related
- 2010-06-29 CA CA2765475A patent/CA2765475A1/en not_active Abandoned
- 2010-06-29 TW TW099121305A patent/TW201103922A/zh unknown
- 2010-06-29 EP EP10794458.9A patent/EP2448934B1/en active Active
- 2010-06-29 UY UY0001032744A patent/UY32744A/es unknown
- 2010-06-29 RU RU2011152516/04A patent/RU2011152516A/ru not_active Application Discontinuation
- 2010-06-29 AU AU2010266753A patent/AU2010266753B2/en not_active Ceased
- 2010-06-29 BR BRPI1014222A patent/BRPI1014222A2/pt not_active IP Right Cessation
- 2010-06-29 JP JP2012518512A patent/JP5767211B2/ja not_active Expired - Fee Related
- 2010-06-29 KR KR1020117031427A patent/KR20120110000A/ko not_active Withdrawn
- 2010-06-29 WO PCT/SE2010/050747 patent/WO2011002405A1/en not_active Ceased
- 2010-06-29 CN CN201080038560.6A patent/CN102482264B/zh not_active Expired - Fee Related
- 2010-06-29 MX MX2011013449A patent/MX2011013449A/es active IP Right Grant
- 2010-06-30 AR ARP100102339A patent/AR077301A1/es unknown
-
2013
- 2013-02-04 US US13/758,098 patent/US8859534B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI1014222A2 (pt) | 2017-05-16 |
| US20100331341A1 (en) | 2010-12-30 |
| CA2765475A1 (en) | 2011-01-06 |
| AU2010266753B2 (en) | 2013-08-08 |
| TW201103922A (en) | 2011-02-01 |
| US8859534B2 (en) | 2014-10-14 |
| US20130296296A1 (en) | 2013-11-07 |
| EP2448934B1 (en) | 2014-05-21 |
| CN102482264A (zh) | 2012-05-30 |
| AU2010266753A1 (en) | 2012-01-19 |
| WO2011002405A1 (en) | 2011-01-06 |
| EP2448934A4 (en) | 2012-12-05 |
| US8367676B2 (en) | 2013-02-05 |
| AR077301A1 (es) | 2011-08-17 |
| EP2448934A1 (en) | 2012-05-09 |
| JP5767211B2 (ja) | 2015-08-19 |
| CN102482264B (zh) | 2015-10-07 |
| UY32744A (es) | 2011-01-31 |
| RU2011152516A (ru) | 2013-08-10 |
| JP2012532125A (ja) | 2012-12-13 |
| MX2011013449A (es) | 2012-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20120110000A (ko) | 2-카르복스아미드-7-피페라지닐-벤조푸란 유도체 774 | |
| JP7470058B2 (ja) | 複素環化合物 | |
| JP5705748B2 (ja) | Ｃｂ２受容体を変調する複素環化合物 | |
| JP5324437B2 (ja) | ５−ｈｔ６モジュレーターとしてのインドール | |
| CA2671990A1 (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | |
| JPWO2000071517A1 (ja) | フェノキシプロピルアミン化合物 | |
| WO2008148853A1 (en) | N-phenyl hydrazides as modulators of the ghrelin receptor | |
| WO2005058858A1 (en) | Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder | |
| KR20120048618A (ko) | 신규한 아릴피페라진-함유 이미다졸 4-카복사마이드 유도체 및 이를 포함하는 약학 조성물 | |
| JP4739230B2 (ja) | ５−ｈｔ６受容体関連疾患の予防または処置に用いられ得る新規ベンゾフラン誘導体 | |
| EP2655365B1 (en) | 2-carboxamide-4-piperazinyl-benzofuran derivative | |
| KR20090127286A (ko) | 히스타민 ｈ３ 수용체 조절제로서의 인돌 및 벤조티오펜 화합물 | |
| JP5789888B2 (ja) | ロイコトリエン生成のベンゾイミダゾールインヒビター | |
| WO2008000818A1 (en) | Fluorinated indoleamides useful as ligands of the orl-1 receptor | |
| JP4655276B2 (ja) | ピラゾロピリミジン化合物のメタンスルホン酸塩、その結晶およびその製造方法 | |
| JP7653399B2 (ja) | オキサジアゾール誘導体を含有する医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PC1203 | Withdrawal of no request for examination |
St.27 status event code: N-1-6-B10-B12-nap-PC1203 |
|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |